New drug combo for newly diagnosed AL amyloidosis
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests a new drug (SCTC21C) combined with three standard chemotherapy medicines for people who have just been diagnosed with AL amyloidosis. The goal is to see if adding the new drug helps reduce the abnormal protein deposits better than the standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with AL amyloidosis (the type caused by abnormal light-chain proteins).
- The disease is measurable – meaning doctors can track it with tests.
- At least one of your organs (like heart, kidneys, or liver) is affected by amyloidosis.
- You are able to care for yourself and are up and about more than half the day.
- You have not received any prior treatment for AL amyloidosis.
- You do not have an uncontrolled infection or other serious medical conditions that would interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (belantamab mafodotin, cyclophosphamide, bortezomib, and dexamethasone) for people newly diagnosed with AL amyloidosis who cannot have a stem cell transplant. The goal is to see if this combination is safe and effective at stopping the abnormal proteins from damaging your organs.
This trial tests a combination of three drugs—bortezomib, pomalidomide, and dexamethasone—to see how well they work for people with AL amyloidosis, a condition where abnormal proteins build up in organs. You may join if you are newly diagnosed or have had prior treatment and your organs are affected.
This trial tests a combination of two targeted drugs for people newly diagnosed with AL amyloidosis. You may qualify if you have a specific genetic marker (t(11;14)) and your organs are working well enough.
This trial tests a new drug combination for people with a specific type of AL amyloidosis (light chain amyloidosis) that has a genetic marker called t(11;14). The treatment includes Sonrotoclax (a targeted therapy) plus steroids, and possibly another drug called daratumumab, to see if it can help control the disease.
This trial tests a new bispecific antibody treatment for people newly diagnosed with AL amyloidosis. The drug targets BCMA on myeloma cells and CD3 on immune cells to help your body fight the disease.
This trial tests a new CAR-T cell therapy (GC012F) that targets two proteins, CD19 and BCMA, on abnormal plasma cells. It's for people with AL amyloidosis who have already tried at least one treatment.
Hear when a new Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.